CRLComplete Response Letter
Complete Response Letter ELC Group (May 29, 2015)
FDA's complete response letter contains source-text evidence related to Labeling, packaging, and proprietary name, Chemistry, manufacturing, and controls, Clinical efficacy and substantial evidence, Safety and adverse events. Theme counts identify where the letter discusses a topic; they do not replace review of the exact redacted letter.
Issued
US FDA• LEUPROLIDE ACETATE FOR DEPOT SUSPENSION
